A new life for rituximab?

Affiliations

¹ Università Vita-Salute and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, MI 20132, Italy. Electronic address: ghia.paolo@hsr.it.

Comment

Paolo Ghia. Lancet Haematol. 2016 Mar.

. 2016 Mar;3(3):e103-4.

doi: 10.1016/S2352-3026(16)00024-7.

¹ Università Vita-Salute and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, MI 20132, Italy. Electronic address: ghia.paolo@hsr.it.

No abstract available

Comment on

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, Brewster M, Catalani O, Li S, McIntyre C, Sayyed P, Badoux X. Assouline S, et al. Lancet Haematol. 2016 Mar;3(3):e128-38. doi: 10.1016/S2352-3026(16)00004-1. Lancet Haematol. 2016. PMID: 26947201 Clinical Trial.